Psoriasis Publications

Click on the title to see the full article:

Secukinumab Provides Complete or Almost Complete Psoriasis Clearance in Moderate to Severe Plaque Psoriasis Pooled Analysis of 4 Phase 3 Trials

Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult to treat nail and scalp psoraisis Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM

Secukinumab Efficacy Stratified by Body Weight: A Subanalysis From the ERASURE Phase 3 Study in Psoriasis

Esteem poster- EADV and Australian College of  Derms

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis

Infectious, Oncologic, and Autoimmune Comorbidities of Psoriasis and Psoriatic Arthritis

Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy subanalysis from the phase 3 FIXTURE study

Efficacy and safety of mirikizumab  LY3074828 in thetreatment of moderate to severe plaque psoriasis  resultsfrom a randomized phase II study

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis

Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3

Secukinumab Provides Complete or Almost-complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial